Inclusion Criteria:  voluntarily participate in the trial, sign the informed consent form, and follow up according to the time specified by the trial; 18~75 years old, without gender limit; Superficial or deep corneal progressive neovascularization induced by trauma, chemical burns, corneal transplantation and inflammation: the growth of corneal new vessels≥ 2 mm from the limbus within 1 week to 2 months.  Exclusion Criteria:  Obvious corneal epithelial defects (>1mm), or a history of persistent corneal epithelial defects in the past 3 months (>1mm, ≥14 days); Anti-VEGF drugs have been injected locally in the target eye within 3 months, or anti-VEGF drugs have been used systemically within 2 months; Recent eye surgery (except for keratoplasty) within 3 months, or planned eye surgery during the trial period; Systemic use of glucocorticoid drugs, or intraocular or periocular injection of glucocorticoid drugs within 1 month; Contact lenses use within the past 2 weeks (except bandage lenses); Stable corneal neovascularization: > 6 months; History of coagulation abnormalities (such as end-stage liver disease), or current anticoagulant drugs other than aspirin (such as warfarin, heparin, enoxaparin or similar anticoagulants); Uncontrolled clinical problems (such as tumors, HIV infection, hepatitis C virus infection, active hepatitis B or other serious chronic infections, serious mental, neurological, cardiovascular, urinary, respiratory and other system diseases, etc.); Uncontrolled hypertension: systolic blood pressure ≥150mmHg or diastolic blood pressure ≥90mmHg; uncontrolled diabetes: A1C>7%; Unwillingness/inability to take effective contraceptive measures during the trial period; Female subjects have a positive blood pregnancy test; Participated in a drug clinical trial within 3 months; The investigator believes that it is not suitable for inclusion.